Oncology and neurosciences are among disease areas of focus for new pRED French R&D Institute.
Roche has launched a new R&D institute focused on conducting collaborative translational medicine with French academic centers. The new institute will be overseen by Roche’s Pharma Research and Early Development (pRED) unit.
The pRED French R&D Institute will work to build in-depth strategic partnerships between Roche and French institutions “in areas of mutual interest,” according to Roche, with the goals of leveraging their expertise, technology platforms, and scientific breakthroughs.
Roche expects the institute to spearhead academic collaborations in France across disease areas and scientific disciplines that include oncology, neurosciences, metabolism, inflammation, virology, translational research, and toxicology. The institute will be managed by a dedicated academic alliances group.
The new institute is the latest in Roche’s network of external research “hubs”, joining academic collaborations with multiple investigators and universities in Singapore; The Netherlands; and the Swiss cities of Basel and Geneva. In France, Roche has 48 ongoing research programs with public partners in oncology, nephrology, virology, and Alzheimer disease.
